230 related articles for article (PubMed ID: 32549918)
1. Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes.
Li N; Zhan X
EPMA J; 2020 Jun; 11(2):289-309. PubMed ID: 32549918
[TBL] [Abstract][Full Text] [Related]
2. Identification of clinical trait-related lncRNA and mRNA biomarkers with weighted gene co-expression network analysis as useful tool for personalized medicine in ovarian cancer.
Li N; Zhan X
EPMA J; 2019 Sep; 10(3):273-290. PubMed ID: 31462944
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer.
Zheng J; Guo J; Cao B; Zhou Y; Tong J
Cancer Cell Int; 2021 Jul; 21(1):363. PubMed ID: 34238292
[TBL] [Abstract][Full Text] [Related]
4. Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer.
Li N; Yu K; Huang D; Li S; Zeng D; Li J; Fan L
Biol Trace Elem Res; 2024 Apr; 202(4):1428-1445. PubMed ID: 37528285
[TBL] [Abstract][Full Text] [Related]
5. SILAC quantitative proteomics analysis of ivermectin-related proteomic profiling and molecular network alterations in human ovarian cancer cells.
Li N; Li J; Desiderio DM; Zhan X
J Mass Spectrom; 2021 Jan; 56(1):e4659. PubMed ID: 33047383
[TBL] [Abstract][Full Text] [Related]
6. Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine.
Li N; Li H; Wang Y; Cao L; Zhan X
EPMA J; 2020 Dec; 11(4):661-694. PubMed ID: 33240452
[TBL] [Abstract][Full Text] [Related]
7. Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization.
Liang R; Zhi Y; Zheng G; Zhang B; Zhu H; Wang M
Onco Targets Ther; 2019; 12():157-168. PubMed ID: 30613154
[TBL] [Abstract][Full Text] [Related]
8. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of lncRNA FAM83H-AS1 in ovarian cancer.
Gong YB; Zou YF
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4656-4662. PubMed ID: 31210291
[TBL] [Abstract][Full Text] [Related]
10. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients.
He Y; Ye Y; Tian W; Qiu H
Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662
[No Abstract] [Full Text] [Related]
11. Derivation, Comprehensive Analysis, and Assay Validation of a Pyroptosis-Related lncRNA Prognostic Signature in Patients With Ovarian Cancer.
Cao X; Zhang Q; Zhu Y; Huo X; Bao J; Su M
Front Oncol; 2022; 12():780950. PubMed ID: 35280739
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of the long non-coding RNA SPRY4-IT1 indicates a poor prognosis and promotes tumorigenesis in ovarian cancer.
Li H; Liu C; Lu Z; Chen L; Wang J; Li Y; Ma H
Biomed Pharmacother; 2017 Apr; 88():529-534. PubMed ID: 28129625
[TBL] [Abstract][Full Text] [Related]
13. Development and verification of a 7-lncRNA prognostic model based on tumor immunity for patients with ovarian cancer.
Feng J; Yu Y; Yin W; Qian S
J Ovarian Res; 2023 Feb; 16(1):31. PubMed ID: 36739404
[TBL] [Abstract][Full Text] [Related]
14. PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.
Chen B; Lu X; Zhou Q; Chen Q; Zhu S; Li G; Liu H
PLoS One; 2023; 18(8):e0290031. PubMed ID: 37582104
[TBL] [Abstract][Full Text] [Related]
15. LEMD1-AS1 Suppresses Ovarian Cancer Progression Through Regulating miR-183-5p/TP53 Axis.
Guo R; Qin Y
Onco Targets Ther; 2020; 13():7387-7398. PubMed ID: 32801762
[TBL] [Abstract][Full Text] [Related]
16. A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer.
Du X; Pu X; Wang X; Zhang Y; Jiang T; Ge Y; Zhu H
Front Genet; 2022; 13():938250. PubMed ID: 36561319
[No Abstract] [Full Text] [Related]
17. Identification of pathology-specific regulators of m
Li N; Zhan X
EPMA J; 2020 Sep; 11(3):485-504. PubMed ID: 32849929
[TBL] [Abstract][Full Text] [Related]
18. EIF4A3 stabilizes the expression of lncRNA AGAP2-AS1 to activate cancer-associated fibroblasts via MyD88/NF-κb signaling.
Xu Q; Zhao T; Han H; Fan J; Xie W
Thorac Cancer; 2023 Feb; 14(5):450-461. PubMed ID: 36541122
[TBL] [Abstract][Full Text] [Related]
19. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
Zhao Q; Fan C
BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
Song Y; Qu H
BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
